Susan Thrane
Member of:
VAR2CSA team
The VLP group (VAR2CSA team) is using a virus-like-particle (VLP) based platform to adjuvant antigens for vaccine purposes. I am involved in vaccine production, formulation, quality assessment and immunization as well as development and optimization of our adjuvanting VLP system.
During my education I have been involved in preclinical studies with different VLP platforms designed to adjuvant low immunogenic antigens especially related to malaria. As a postdoc, I have been involved in using the VLP platform as an immunotherapeutic treatment for HER2 related breast cancer in mice. Several techniques are involved in this process such as; cloning and purification of proteins and VLPs, electron microscopy and dynamic light scattering for quality assessment as well as immunoassays to assess the response to the vaccine.
ID: 45121968
Most downloads
-
553
downloads
Bacterial superglue enables easy development of efficient virus-like particle based vaccines
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
249
downloads
Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
192
downloads
A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses
Research output: Contribution to journal › Journal article › Research › peer-review
Published